“A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also knownas MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA)Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer”

MC #23-13

NCT #
NCT04844073
Condition(s)
Adrenocortical, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Hepatocellular Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma, Thyroid Cancer, Urothelial Cancer
Molecular Target(s)
CD3, EGFR
Drug Classification(s)
Bispecific Monoclonal Antibody
Agents(s)
Phase(s)
I/II

Mechanism of Action

MVC-101 is a EGFR targeting T-cell engaging bispecific antibody

Purpose

  • How much of the study agent can be given with an acceptable level of side effects
  • The effects of the study agent (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from TAK-186

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.